Eli Lilly and Company (NYSE: LLY) Stock Competitors & Peer Comparison
See LLY's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for LLY and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LLY | $1,354.00 | -0.79% | 1.3T | 43.57 | $31.49 | +0.49% |
| JNJ | $276.22 | +1.43% | 664.8B | 25.74 | $10.73 | +1.92% |
| ABBV | $291.31 | +1.07% | 514.9B | 28.59 | $10.19 | +2.39% |
| MRK | $146.73 | -0.14% | 362B | 45.70 | $3.21 | +2.32% |
| NVS | $162.55 | +0.38% | 307B | 18.71 | $8.69 | +2.93% |
| AZN | $186.43 | -0.22% | 289.1B | 20.13 | $9.26 | +1.74% |
| AMGN | $460.42 | +0.03% | 248.8B | 20.57 | $22.37 | +2.16% |
| GILD | $166.89 | -0.41% | 206.9B | -427.74 | -$0.39 | +1.94% |
| NVO | $40.31 | +0.02% | 177.7B | 10.03 | $4.02 | +4.46% |
| PFE | $29.39 | -0.20% | 167.5B | 9.63 | $3.05 | +5.87% |
Stock Comparison
Johnson & Johnson (NYSE: JNJ)
LLY vs JNJ Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, JNJ has a market cap of 664.8B. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while JNJ trades at $276.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas JNJ's P/E ratio is 25.74. In terms of profitability, LLY's ROE is +0.84%, compared to JNJ's ROE of +0.20%. Regarding short-term risk, LLY is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for LLY.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
LLY vs ABBV Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, ABBV has a market cap of 514.9B. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while ABBV trades at $291.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas ABBV's P/E ratio is 28.59. In terms of profitability, LLY's ROE is +0.84%, compared to ABBV's ROE of -2.03%. Regarding short-term risk, LLY is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for LLY.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
LLY vs MRK Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, MRK has a market cap of 362B. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while MRK trades at $146.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas MRK's P/E ratio is 45.70. In terms of profitability, LLY's ROE is +0.84%, compared to MRK's ROE of +0.05%. Regarding short-term risk, LLY is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for LLY.Check MRK's competition here
Novartis AG (NYSE: NVS)
LLY vs NVS Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, NVS has a market cap of 307B. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while NVS trades at $162.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas NVS's P/E ratio is 18.71. In terms of profitability, LLY's ROE is +0.84%, compared to NVS's ROE of +0.25%. Regarding short-term risk, LLY is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for LLY.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
LLY vs AZN Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, AZN has a market cap of 289.1B. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while AZN trades at $186.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas AZN's P/E ratio is 20.13. In terms of profitability, LLY's ROE is +0.84%, compared to AZN's ROE of +0.22%. Regarding short-term risk, LLY is less volatile compared to AZN. This indicates lower risk in terms of short-term price fluctuations for LLY.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
LLY vs AMGN Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, AMGN has a market cap of 248.8B. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while AMGN trades at $460.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas AMGN's P/E ratio is 20.57. In terms of profitability, LLY's ROE is +0.84%, compared to AMGN's ROE of +0.86%. Regarding short-term risk, LLY is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for LLY.Check AMGN's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
LLY vs GILD Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, GILD has a market cap of 206.9B. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while GILD trades at $166.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas GILD's P/E ratio is -427.74. In terms of profitability, LLY's ROE is +0.84%, compared to GILD's ROE of -0.22%. Regarding short-term risk, LLY is more volatile compared to GILD. This indicates higher risk in terms of short-term price fluctuations for LLY.Check GILD's competition here
Novo Nordisk A/S (NYSE: NVO)
LLY vs NVO Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, NVO has a market cap of 177.7B. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while NVO trades at $40.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas NVO's P/E ratio is 10.03. In terms of profitability, LLY's ROE is +0.84%, compared to NVO's ROE of +0.54%. Regarding short-term risk, LLY is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for LLY.Check NVO's competition here
Pfizer Inc. (NYSE: PFE)
LLY vs PFE Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, PFE has a market cap of 167.5B. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while PFE trades at $29.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas PFE's P/E ratio is 9.63. In terms of profitability, LLY's ROE is +0.84%, compared to PFE's ROE of +0.05%. Regarding short-term risk, LLY is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for LLY.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
LLY vs BMY Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, BMY has a market cap of 127.1B. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while BMY trades at $62.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas BMY's P/E ratio is 10.48. In terms of profitability, LLY's ROE is +0.84%, compared to BMY's ROE of +0.44%. Regarding short-term risk, LLY is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for LLY.Check BMY's competition here
Sanofi (NASDAQ: SNY)
LLY vs SNY Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, SNY has a market cap of 113.7B. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while SNY trades at $47.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas SNY's P/E ratio is 10.24. In terms of profitability, LLY's ROE is +0.84%, compared to SNY's ROE of +0.06%. Regarding short-term risk, LLY is less volatile compared to SNY. This indicates lower risk in terms of short-term price fluctuations for LLY.Check SNY's competition here
GSK plc (NYSE: GSK)
LLY vs GSK Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, GSK has a market cap of 101.8B. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while GSK trades at $50.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas GSK's P/E ratio is 10.87. In terms of profitability, LLY's ROE is +0.84%, compared to GSK's ROE of +0.23%. Regarding short-term risk, LLY is less volatile compared to GSK. This indicates lower risk in terms of short-term price fluctuations for LLY.Check GSK's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
LLY vs CELG-RI Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, CELG-RI has a market cap of 94.8B. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while CELG-RI trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, LLY's ROE is +0.84%, compared to CELG-RI's ROE of +0.44%. Regarding short-term risk, LLY is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for LLY.Check CELG-RI's competition here
Biogen Inc. (NASDAQ: BIIB)
LLY vs BIIB Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, BIIB has a market cap of 36.7B. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while BIIB trades at $248.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas BIIB's P/E ratio is 15.69. In terms of profitability, LLY's ROE is +0.84%, compared to BIIB's ROE of +0.02%. Regarding short-term risk, LLY is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for LLY.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
LLY vs HZNP Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas HZNP's P/E ratio is 61.86. In terms of profitability, LLY's ROE is +0.84%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, LLY is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for LLY.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
LLY vs GRFS Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, GRFS has a market cap of 7.1B. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while GRFS trades at $8.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas GRFS's P/E ratio is 9.69. In terms of profitability, LLY's ROE is +0.84%, compared to GRFS's ROE of +0.09%. Regarding short-term risk, LLY is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for LLY.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
LLY vs OGN Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while OGN trades at $13.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas OGN's P/E ratio is 4.13. In terms of profitability, LLY's ROE is +0.84%, compared to OGN's ROE of +0.22%. Regarding short-term risk, LLY is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for LLY.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
LLY vs AMRN Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, AMRN has a market cap of 241.1M. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while AMRN trades at $11.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas AMRN's P/E ratio is -116.55. In terms of profitability, LLY's ROE is +0.84%, compared to AMRN's ROE of -0.04%. Regarding short-term risk, LLY is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for LLY.Check AMRN's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
LLY vs MIRA Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, MIRA has a market cap of 23.3M. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while MIRA trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas MIRA's P/E ratio is -0.38. In terms of profitability, LLY's ROE is +0.84%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, LLY is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for LLY.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLX)
LLY vs SCLX Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, SCLX has a market cap of 11.7M. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while SCLX trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas SCLX's P/E ratio is -0.04. In terms of profitability, LLY's ROE is +0.84%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, LLY is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for LLY.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
LLY vs SCLXW Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, SCLXW has a market cap of 7.6M. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while SCLXW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas SCLXW's P/E ratio is N/A. In terms of profitability, LLY's ROE is +0.84%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, LLY is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for LLY.Check SCLXW's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
LLY vs BDSIW Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, LLY's ROE is +0.84%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, LLY is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for LLY.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
LLY vs CRXT Comparison November 2026
Eli Lilly and Company (NYSE: LLY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 1.3T. In comparison, CRXT has a market cap of 0. Regarding current trading prices, LLY is priced at $1,354.00 on the NYSE, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 43.57, whereas CRXT's P/E ratio is -0.02. In terms of profitability, LLY's ROE is +0.84%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, LLY is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for LLY.Check CRXT's competition here